Vidarabine

CHEMBL1090 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
267.2 g/mol
LogP
-1.1
Phase
4

Vidarabine (adenine arabinoside, Ara-A) is a purine nucleoside analog that is phosphorylated intracellularly to vidarabine triphosphate, which inhibits viral DNA polymerases and DNA primase, blocking viral DNA replication with selectivity for herpes viruses. It was used topically for herpes simplex keratitis and systemically for herpes encephalitis and neonatal herpes, but has largely been replaced by acyclovir due to the latter's improved safety and efficacy profile. Its antiviral mechanism targeting viral DNA polymerase established the template for subsequent nucleoside analog antivirals.

น้ำหนักโมเลกุล

267.2400 g/mol

LogP

-1.10

TPSA

140.00 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

กลไกการออกฤทธิ์

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O

InChI

InChI=1S/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6-,7+,10-/m1/s1

Molecular Formula

C10H13N5O4

HBD / HBA

4 / 8

พันธะที่หมุนได้

2

อะตอมหนัก

19

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

Vidarabine (adenine arabinoside, Ara-A) is a purine nucleoside analog that is phosphorylated intracellularly to vidarabine triphosphate, which inhibits viral DNA polymerases and DNA primase, blocking viral DNA replication with selectivity for herpes viruses. It was used topically for herpes simplex keratitis and systemically for herpes encephalitis and neonatal herpes, but has largely been replaced by acyclovir due to the latter's improved safety and efficacy profile. Its antiviral mechanism targeting viral DNA polymerase established the template for subsequent nucleoside analog antivirals.

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Yes, Vidarabine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1090. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 21704. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.